{"id":20914,"date":"2022-05-23T14:43:16","date_gmt":"2022-05-23T13:43:16","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=20914"},"modified":"2024-06-26T17:02:57","modified_gmt":"2024-06-26T16:02:57","slug":"developing-materials-overcome-amr-orthopaedic-implants","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/developing-materials-overcome-amr-orthopaedic-implants\/20914\/","title":{"rendered":"Developing materials to overcome AMR in orthopaedic implants"},"content":{"rendered":"

AIMed is a Marie Sklodowska-Curie Innovative Training Network (Horizon2020 MSCA-ITN) training 15 early-stage researchers to develop materials with antimicrobial properties suitable for use on the surfaces of orthopaedic implants to counter the increasing problem of post-operative infection by antibiotic-resistant bacteria.<\/h2>\n

Current challenges in orthopaedic implant surgery<\/h3>\n

There are thousands of medical device classes regulated by MHRA and FDA to verify that medical devices approved to be marketed in the United Kingdom and the United States are safe and applicable.<\/p>\n

Although these devices save and ameliorate the quality of patients’ lives, one challenge is the potential infection of implanted devices associated with bacterial colonisation and biofilm formation. The biofilm development compromises the immune process at the tissue\/implant interface, extends the period of antibiotic therapy, and results in further surgical procedures.<\/p>\n

As well as this, bacterial cells in these biofilms can result in a significant increase in antibiotic resistance. Consequently, despite using systemic antibiotic therapy and aseptic surgery procedures, implant infections acquired in hospitals still cause remarkable morbidity and mortality.<\/p>\n

What are the key areas of AIMed?<\/h3>\n

The AIMed network carries out a thorough investigation of the properties of new materials and antimicrobial coatings to ensure that they are feasible for use in future implants. On top of this, the network evaluates antibacterial activity and biocompatibility using appropriate models.<\/p>\n

AIMed aims to:<\/p>\n